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Abstract: The unexpected tendency of amines and functionalized hydrazines to reduce 
ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1) to afford a quinoxaline 1c and 
mono-oxide quinoxalines 1a and 1b is described. The experimental conditions were 
standardized to the use of two equivalents of amine in ethanol under reflux for two hours, 
with the aim of studying the distinct reductive profiles of the amines and the 
chemoselectivity of the process. With the exception of hydrazine hydrate, which reduced 
compound 1 to a 3-phenyl-2-quinoxalinecarbohydrazide derivative, the amines only acted 
as reducing agents. 
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Introduction 
 
Quinoxaline and quinoxaline 1,4-di-N-oxide are heterocycles that are often used in the synthesis of 
biologically active compounds [1-31]. The former is described as a bioisoster of the quinoline, 
naphthyl, benzothienyl and other aromatic rings [32], and it can be found in the structure of anti-
bacterial [1], anti-tuberculosis [5-7, 9-11, 13, 14, 16, 22], anti-cancer [8, 18, 20, 28], anti-malarial [12, 
24, 26, 29-31], anti-Chagas [15, 25] and anti-inflammatory [19, 27] drug candidates. The widespread 
activity of quinoxaline 1,4-di-N-oxides can be associated with the generation of free radicals [33]. In 
our continuing efforts to find quinoxaline-1,4-di-N-oxide derivatives with anti-malarial activity [12, 
23, 24, 26, 29-31], the conversion of compound 1 into hydrazides 2 and amide derivatives 3 was 
carried out by means of hydrazinolysis and aminolysis reactions, in which unexpected results were 
obtained. In this work we describe the reducing profiles of amine derivatives when they act upon the 
ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide derivative 1.  
Scheme 1. Design of new quinoxaline 1,4-di-N-oxide derivatives. 
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Results and Discussion 
 
In a continuing effort to synthesize new anti-malarial drug candidates, we wished to substitute the 
carboethoxy moiety present in lead-compound 1, with a functionalized hydrazide subunit 2 (Scheme 
1). For this purpose compound 1 was first treated with phenylhydrazine in the presence of ethanol 
under reflux for two hours. After workup, the crude oil was analyzed by 1H-NMR, which revealed the 
presence of four different carboethoxy group signals. This crude oil was purified by silica gel column 
chromatography and the separated products analyzed by 1H-NMR, IR, mass spectra and elemental 
analyses. From these analyses, it was observed that the reaction with phenylhydrazine had failed to 
produce the functionalized hydrazide derivative 2, but rather this reaction surprisingly gave a mixture 
of quinoxaline 1c, quinoxalines N-4 monoxide 1a, N-1 monoxide 1b and 1,4-di-N-oxide 1 (Table 1). 
While the reducing activity of hydrazine hydrate [34, 35] is well known, the aforementioned 
information was not as clear for phenylhydrazine. In an attempt to determine if the reduction of 1 by 
phenylhydrazine could be influenced by the electronic profile of quinoxaline-ester 1, the derivatives 4-
7, attached to electron-withdrawing and electron-donating groups, were treated with phenylhydrazine 
in ethanol under reflux for two hours; the results are given in Table 1 (entries 2, 3, 4 and 5). These 
results showed no selective reduction for substrates 5-7, with the exception of compound 4 (4’-nitro, 
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σp = 0.81) that could be selectively reduced to quinoxaline 4c (entry 2). In this particular case, 
different reducing profiles were observed for phenylhydrazine and hydrazine hydrate because, with the 
latter no chemoselectivity was observed, and consequently, the nitro group was also reduced and the 
hydrazinolysis product was formed (data not shown). Intrigued by these results, the possibility that 
other amines could act as reducing agents towards the quinoxaline 1,4-di-N-oxide system was then 
studied. Derivative 1, used as template, was treated with different amines (two equivalents) in the 
presence of ethanol under reflux for two hours (Table 1). The results clearly demonstrated the ability 
of hydroxylamine (entry 9), methylamine (entry 10), ethanolamine (entry 11), methyl hydrazine (entry 
6), and 2,4-dinitrophenylhydrazine (entry 7) to reduce compound 1 to the mono-oxide derivatives 1a 
and 1b and to quinoxaline 1c, while amines such as triethylamine (entry 12) and aniline (entry 13), 
were unable to reduce compound 1, as no significant difference was noted when compared to the 
experiment carried out in the absence of amine (entry 14).  
Table 1: Reduction of ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1).  
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Entry Reducing Agent W 
n=n1=1 
(1, 4-7) 
n=0, n1=1
(1b, 4-7a) 
n=1, n1=0 
(1c, 4-7b) 
n=n1=0 
(1a, 4-7c) 
1 PhNHNH2 H 18.1% 30.1% 28.4% 23.4%
2 PhNHNH2 NO2 16.7% 0% 0% 83.3%
3 PhNHNH2 CF3 22.6% 30,0% 23.7% 23.7%
4 PhNHNH2 OCH3 25.7% 28.6% 17.6% 28.1%
5 PhNHNH2 CH3 15.1% 31.8% 21.9% 31.2%
6 H3CNHNH2 H 43.8% 21.8% 22.5% 11.9%
7 2,4-diNO2PhNHNH2 H 57.4% 8.9% 24.1% 9.6%
8 N2H4.H2O H 0% 0% 0% 100%*
9 NH2OH.H2O H 22.6% 8.1% 33.8% 35.5%
10 NH2CH3.H2O H 33.8% 8.0% 49.7% 8.5%
11 NH2(CH2)2OH H 0% 34.2% 36.0% 29.8%
12 Et3N H 80.8% 0% 19.2% 0%
13 PhNH2 H 81.2% 0% 18.8% 0%
14 EtOH H 85.5% 0% 14.5% 0%
15 P(OCH3)3 H 0% 100% 0% 0%
16 Na2S2O4 H 0% 0% 0% 100%
*formation of 3-phenyl-2-quinoxalinecarbohydrazide; absence of chemioselectivity. 
 
The yields were determined by 1H-NMR analysis of total crude product mixtures obtained after the 
work-up of each reaction. The methyl (OCH2CH3) resonances for the four compounds 1, 1a, 1b and 
1c, were observed at different chemical shifts, and thus, integration of the methyl region (OCH2CH3) 
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allowed relative molar percentages to be readily ascertained. The unequivocal structural assignments 
of the N-4 oxide 1a, N-1 oxide 1b and quinoxaline 1c derivatives were accomplished by 1H-NMR, IR, 
mass spectra and elemental analyses. In an attempt to specifically identify mono-oxide quinoxaline 
derivatives (1a versus 1b), a selective mono-deoxygenation of compound 1 was performed (entry 14) 
using trimethylphosphite (entry 15), as previously described by Kluge and coworkers [36]. By this 
methodology, it was only possible to obtain the N-4 oxide derivative 1a, which was characterized by 
1H-NMR; the data was used for direct comparison with the N-oxides obtained from the reaction with 
the amines. In a similar way, the quinoxaline di-N-oxide 1 was totally reduced to quinoxaline 1c, using 
Na2S2O4 (entry 16) in a mixture of methanol and water [37, 24]; the chemical shift of compound 1c 
was measured by 1H-NMR and compared with the products obtained from amine reductions. 
Compounds 1a, 1b and 1c were evaluated for their ability to inhibit P. falciparum (chloroquine 
sensitive), and were shown to be inactive as anti-malarial agents (data not shown). 
 
Conclusions 
 
In summary, this work clearly demonstrates a tendency of amines and functionalized hydrazines to 
reduce ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1) to a quinoxaline 1c and mono-
oxides quinoxalines 1a and 1b. Although the starting material 1 was recovered in most of the reactions 
(entries 1-7, 9-10, 12-14), suggesting that a longer time reaction could be necessary, the experimental 
conditions were standardized in two hours, using two equivalents of amine, with the aim of studying 
the distinct reductive profile of the amine used and the chemoselectivity of the process. With the 
exception of hydrazine hydrate, a well-known reducing agent, which reduced compound 1 to a 3-
phenyl-2-quinoxalinecarbohydrazide derivative, the amines were unable to act as nucleophiles and 
acted exclusively as reducing agents. Compounds 1a, 1b and 1c were inactive as antimalarial agents. 
 
Experimental  
 
General 
 
All of the synthesized compounds were chemically characterized by thin layer chromatography 
(TLC), infrared (IR), nuclear magnetic resonance (1H-NMR), mass spectra (MS) and elemental 
microanalysis (CHN). Alugram SIL G/UV254 (0.2 mm layer, Macherey-Nagel GmbH & Co. KG. 
Düren, Germany) was used for TLC and Silica gel 60 (0.040-0.063 mm, Merck) for Flash Column 
Chromatography. 1H-NMR spectra were recorded on a Bruker 400 Ultrashield instrument (400 MHz), 
using TMS as the internal standard with CDCl3 as the solvent; the chemical shifts are reported in ppm 
(δ) and coupling constants (J) values are given in Hertz (Hz). Signal multiplicities are represented by: 
s (singlet), d (doublet), t (triplet), q (quadruplet), dd (double doublet) and m (multiplet). IR spectra 
were recorded on a Nicolet Nexus FTIR (Thermo, Madison, USA) in KBr pellets. Mass spectra were 
measured on a MSD/DS 5973N G2577A mass spectrometer (Agilent Technologies, Waldbronn, 
Germany) with a direct insertion probe (DIP). The ionization method was electron impact (EI, 70 eV). 
Elemental microanalyses were obtained on a Leco CHN-900 Elemental Analyzer (Leco, Tres Cantos, 
Spain) from vacuum-dried samples. The analytical results for C, H, and N, were within ± 0.4 of the 
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theoretical values. Chemicals were purchased from Panreac Química S.A. (Barcelona, Spain), Sigma-
Aldrich Química, S.A. (Alcobendas, Spain), Acros Organics (Janssen Pharmaceuticalaan, Geel, 
Belgium) and Lancaster (Bischheim-Strasbourg, France). 
 
General procedure for the reduction of ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1) 
 
Ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1, 1 mmol) was added to ethanol (10 
mL) and the amine derivative (1 mmol). The mixture was refluxed for two hours, then the reactions 
were worked-up by adding CH2Cl2 (50 mL), followed by extraction with 10% aqueous HCl (4 x 15 
mL). The organic layer was dried (Na2SO4), filtered, and evaporated to dryness. The yields were 
determined by 1H-NMR analysis of the total crude product mixture. The residue was later purified by 
silica gel column chromatography (n-hexane-ethyl acetate). 
 
Ethyl 3-phenylquinoxaline-2-carboxylate 1,4-di-N-oxide (1). 1H-NMR: δ 1.08 (t, J= 7.2 Hz, 3H, 
OCH2CH3); 4.25 (t, J= 7.2 Hz, 2H, OCH2CH3); 7.53 (m, 3H, H3’-H5’); 7.61 (m, 2H, H2’ and H6’); 
7.91 (m, 2H, H6 and H7); 8.65 (m, 2H, H5 and H8) ppm; 13C-NMR: δ 13.98 (OCH2CH3), 63.65 
(OCH2CH3), 120.89 (C5), 121.08 (C8), 127.84 (C1’), 129.16 (C3’ and C5’), 130.15 (C2’ and C6’), 
131.26 (C4’), 132.51 (C6), 132.53 (C7), 136.53 (C2), 137.73 (C10), 138.81 (C3), 140.08 (C9), 159.66 
(CO2Et) ppm; IR: 2978 (ArC-H), 1746 (C=O), 1352 (N-oxide), 701 and 666 (monosubstituted phenyl) 
cm-1; MS: 310 (m/z, 100%), 294 (M+, 6%), 249 (M+, 51%), 221 (M+, 46%), 77 (M+, 46%); Anal. 
calcd. for C17H14N2O4: C, 65.80; H, 4.52; N, 9.03. Found: C, 65.65; H, 4.57; N, 8.98. 
 
Ethyl 3-phenylquinoxaline-2-carboxylate 4-N-oxide (1a). 1H-NMR: δ 1.04 (t, J=7.2 Hz; 3H, 
OCH2CH3); 4.20 (q, J=7.2 Hz; 2H, OCH2CH3); 7.56 (m, 3H, H3’-H5’); 7.61 (m, 2H, H2’and H6’); 
7.88 (m, 2H, H6 and H7); 8.26 (dd, J= 1.2, 8.2 Hz; 1H, H5); 8.65 (dd, J= 1.2, 7.6 Hz; 1H, H8); IR: 
2981 (ArC-H), 1742 (C=O), 1359 (N-oxide), 701 and 666 (monosubstituted phenyl) cm-1; MS: 294 
(m/z, 65%), 265 (M+, 13%), 249 (M+, 26%), 221 (M+, 100%), 77 (M+, 18%); Anal. calcd. for 
C17H14N2O3: C, 69.38; H, 4.79; N, 9.52. Found: C, 69.37; H, 4.77; N, 9.51. 
 
Ethyl 3-phenylquinoxaline-2-carboxylate 1-N-oxide (1b). 1H-NMR: δ 1.25 (t, J=7.2 Hz; 3H, 
OCH2CH3); 4.42 (q, J=7.2 Hz; 2H, OCH2CH3); 7.54 (m, 3H, H3’-H5’); 7.80 (m, 3H, H2’and H6’ and 
H7); 7.89 (dt, J= 8.4, 7.6 Hz; 1H, H6); 8.20 (d, J= 8.4 Hz; 1H, H5); 8.61 (d, J= 8.0 Hz; 1H, H8); IR 
(KBr): 2979 (ArC-H), 1735 (C=O), 1363 (N-oxide), 701 and 671 (monosubstituted phenyl) cm-1; MS: 
294 (m/z, 60%), 265 (M+, 9%), 249 (M+, 31%), 221 (M+, 100%), 77 (M+, 26%); Anal. calcd. for 
C17H14N2O3: C, 69.38; H, 4.79; N, 9.52. Found: C, 69.39; H, 4.80; N, 9.51. 
 
Ethyl 3-phenylquinoxaline-2-carboxylate (1c). 1H-NMR:  δ 1.19 (t, J=7.2 Hz; 3H, OCH2CH3); 4.34 (q, 
J=7.2 Hz; 2H, OCH2CH3); 7.53 (m, 3H, H3’-H5’); 7.76 (m, 2H, H2’and H6’); 7.85 (m, 2H, H6 and 
H7); 8.20 (d, J= 8.0 Hz; 1H, H5); 8.24 (d, J= 7.6 Hz; 1H, H8); IR: 2990 (ArC-H), 1730 (C=O), 711 
and 669 (monosubstituted phenyl) cm-1; MS: 278 (m/z, 33%), 249 (M+, 26%), 234 (M+, 15%), 206 
(M+, 100%), 77 (M+, 33%); Anal. calcd. for C17H14N2O2: C, 73.37; H, 5.07; N, 10.07. Found: C, 73.35; 
H, 5.08; N, 10.05. 
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